AlphAIAlphAI — Financial news for AI agents
stockstory.orgSEP 223 min read$ABBV

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) reported Q2 revenue of $16.99B, up 10.2% YoY, beating estimates by 1.2%. Biogen (NASDAQ:BIIB) saw revenue rise 3.4% YoY, exceeding expectations by 12.1%. Myriad Genetics (NASDAQ:MYGN) reported a 10.5% YoY revenue decline, missing estimates by 8.2%. Gilead Sciences (NASDAQ:GILD) reported $7.80B in revenue, up 10.2% YoY, beating estimates by 6.2%. Moderna (NASDAQ:MRNA) reported $145M in revenue, up 2.1% YoY, surpassing expectations by 35.8%.

Original reporting
stockstory.org
Published Sep 22, 2026, 9:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 9:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV) — source image
Source · stockstory.org
Decision brief

The 30-second read

$ABBVBullishLow
01

Why it matters

Overall, earnings beats drive short‑term rallies in several stocks, while misses lead to sharp declines, suggesting sector rotation based on quarterly performance.

02

Market read

Earnings recap provides a snapshot of sector performance but offers limited new actionable insight.

03

What to watch

Potential headwinds from drug pricing scrutiny and regulatory uncertainty could dampen future growth.

Relevance 4/10Novelty 2/10Timing: none

Background

The article reviews Q2 results for a group of therapeutic companies, highlighting revenue beats, misses, and stock price reactions.

Company-level read

Ticker impact

$ABBVBullishMedium confidence
Context

AbbVie reported Q2 revenue of $16.99B, beating estimates by 1.2% and its stock rose 2.9% after the release.

Expected impact

Small upside potential if momentum continues.

Evidence & confidence

Revenue beat but EPS guidance miss limits upside.

$BIIBBullishMedium confidence
Context

Biogen posted Q2 revenue of $2.74B, beating estimates by 12.1% and its shares rose 6.6% post‑earnings.

Expected impact

Potential further gains if beat sustains.

Evidence & confidence

Strong beat and price reaction suggest short‑term buying interest.

$MYGNBearishMedium confidence
Context

Myriad Genetics reported Q2 revenue of $190.7M, down 10.5% YoY and missed estimates by 8.2%, with the stock down 25.3% since the report.

Expected impact

Further decline likely unless guidance improves.

Evidence & confidence

Revenue decline and miss on guidance drive bearish sentiment.

$GILDBullishMedium confidence
Context

Gilead Sciences posted Q2 revenue of $7.80B, up 10.2% YoY and beat estimates by 6.2%, with the stock up 10.4% after the release.

Expected impact

Likely continued upside on momentum.

Evidence & confidence

Revenue growth and beat reinforce positive sentiment.

$MRNABullishMedium confidence
Context

Moderna reported Q2 revenue of $145M, up 2.1% YoY and beat estimates by 35.8%, sending the stock up 199% since the report.

Expected impact

Short‑term upside may be limited after large run‑up.

Evidence & confidence

Huge beat and price surge suggest near‑term profit taking.

Market effects

Sector

Therapeutics sector shows mixed earnings; strong beats for some firms may lift sector sentiment.

Regional

U.S. biotech earnings influence domestic biotech ETFs and related indices.

Global

Limited to investors focused on U.S. pharma and biotech equities.

Counterpoint

What could challenge this read

Despite earnings beats, valuation multiples remain elevated; caution on overbought conditions.

Key entities

  • Company
    AbbVie

    Biopharma firm reporting Q2 earnings.

  • Company
    Biogen

    Neurology‑focused biotech reporting Q2 earnings.

  • Company
    Myriad Genetics

    Genetic testing company reporting Q2 earnings.

  • Company
    Gilead Sciences

    Antiviral and oncology drug maker reporting Q2 earnings.

  • Company
    Moderna

    mRNA therapeutics developer reporting Q2 earnings.

Read at source← All news

Related articles

OCT 15
$ABBVMed

What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?

AbbVie (ABBV) and Genmab reported positive Phase 3 trial results for epcoritamab plus R-CHOP in high-risk diffuse large B-cell lymphoma, showing a 51% reduction in disease progression or death risk. The data suggest potential for front-line treatment, supporting AbbVie's oncology ambitions and revenue diversification. Regulatory filings and approvals will be key next steps.

finance.yahoo.com2 min
OCT 15
$MRNAMed

Moderna Stock Jumps 4.5% as Major Cancer Vaccine Catalyst Approaches

Moderna (MRNA) shares rose 4.5% as investors await detailed results from a Phase 3 cancer trial with Merck (MRK). The trial, involving 1,137 patients, showed the treatment reduced cancer recurrence. Results will be presented on October 24. Moderna reported a Q2 net loss of $782 million. Barclays estimates potential $3 billion annual melanoma sales by 2035, split equally with Merck.

tipranks.com6 min
OCT 15
$MRNAMed

Moderna (MRNA) Shares Surge on Cancer Vaccine Data Ahead of Late

Moderna (MRNA) shares rose 38% since late September ahead of a presentation on late-stage trial data for its cancer vaccine, developed with Merck (MRK). The rally follows a 170% surge after positive Phase 3 melanoma trial results in August. Moderna's P/S ratio is 41.76, significantly higher than its historical median of 8.48, reflecting market growth expectations despite its unprofitability. Insider activity shows no purchases and $64.6M in sales over the past year.

gurufocus.com6 min
OCT 15
$GILDHighAI 9/10

Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers

Gilead Sciences and Vir Biotechnology agreed to collaborate on developing T-cell engager therapies for solid tumors. Gilead will pay $90m upfront, including $65m in cash and $25m in equity, with up to $1.74bn in potential milestones. Gilead will lead development and commercialization, using Vir's PRO-XTEN technology and AI platform. This follows their 2021 hepatitis B drug collaboration and Vir's recent deal with Astellas.

finance.yahoo.com2 min
OCT 15
$MRNAHigh

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

Moderna's stock rose 658.2% year-to-date, reaching $223.60 premarket. The surge followed positive late-stage trial results for its cancer vaccine, developed with Merck. Analysts' price targets are below current levels, with a consensus at $122.67. Moderna reports Q3 earnings on November 6, with revenue and cash flow expectations to be revealed. The stock trades at 38.75 times trailing sales, raising valuation concerns.

247wallst.com2 min
OCT 15
$MRNAMed

MRNA Maintains Neutral Rating -- Price Target Raised to $137

Goldman Sachs maintained a Neutral rating on Moderna (MRNA) but raised its price target to $137 from $120. GuruFocus values MRNA at $23.84, suggesting it is 849.2% overvalued. The company has a GF Score of 54/100, with strengths in financial stability but weaknesses in profitability and valuation. Insider selling totaled $49.18M over the past three months.

gurufocus.com2 min